Products
Friends links
|
|

January 10, 2020
Founded in Suzhou, Xiangcheng District
April 2020
Laboratory design and construction initiated for IND&BLA testing
July 2020
Laboratory construction completed
September 2020
Laboratory commissioning and equipment verification completed
Q4 2020
Officially began service for external clients
April 23, 2021
ISO 9001 certification obtained
April 30, 2021
Received CMA certification
June 2021
Received official IND approval in USA
December 2021
Received official IND approval in China
May 2022
Awarded CNAS certification
April 2023
Passed U.S. FDA on-site audit
May 2023
Submitted all test methods, SOPs, and verification reports to the CDE - approved with no objections.
Cefety Bioscience Co., Ltd., established in 2020, is a global provider of biosafety and customized viral testing services for the biopharmaceutical industry.
We serve companies and institutions worldwide, operating in strict compliance with international regulatory standards, including those from China, the United States, Europe, and other major regions.
Our expertise spans hundreds of projects, playing a key role in securing IND and BLA approvals across China, the U.S., Australia, and New Zealand.
We've passed audits and on-site inspections by EU Qualified Persons (QPs) and China's National Medical Products Administration (NMPA), and hold certifications from:
● CMA (China Inspection Body and Laboratory Mandatory Approval)
● CNAS (China National Accreditation Service for Conformity Assessment)
● ISO 9001
● FDA FEI Registration
By strictly adhering to global pharmacopoeias and regulatory frameworks, we ensure data integrity, authenticity, and traceability across all testing.
Our evaluation system supports the quality assessment of Biologics, Cell And Gene Therapies, Nucleic Acid Drugs, and Vaccines, in line with international standards.

Quality Assurance You Can Trust, Globally Aligned
Cefety Bioscience operates a robust quality management system that meets internationally recognized standards, ensuring regulatory compliance, data integrity, and total traceability across all projects.
Our Quality Commitment Includes:
● Certification under CMA, CNAS, and ISO 9001
● Compliance with Chinese and U.S. GLP/GMP regulations
● No-cost audits available in multiple countries
● A fully independent quality department overseeing all testing
● Rigorous validation of methods, test plans, raw data, and reports
● End-to-end traceability and documentation verification
● Expert technical support for IND/BLA applications
Cefety Bioscience offers a comprehensive platform for biosafety testing and viral validation, designed to meet the regulatory and technical requirements of IND/BLA applications in China, the United States, and the European Union.
Our core service areas include:
● MCB/WCB/EOPC cell bank characterization
● MVS/WVS virus bank characterization
● UPB release testing
● Viral clearance validation
All services are performed in compliance with relevant international regulatory standards, ensuring reliable, high-quality results that support global drug development.
1. Cell bank/Virus Bank Characterization and Intermediate Product Release Testing
Establishing a cell or virus bank is a key step in GMP manufacturing - and contamination at this stage can seriously impact product quality and patient safety.
Cefety Bioscience provides comprehensive testing to ensure regulatory compliance and product integrity, including:
● Cell bank and virus bank characterization
● Intermediate product release testing
All testing is conducted in accordance with:
● Chinese, U.S., and European Pharmacopoeias
● U.S. 9 CFR, FDA PTC (1993/1997/2010)
● ICH Q5A and other global standards
Our validated methods and rigorous quality control ensure accurate, compliant results that support safe, effective biologics development.
2. Viral Clearance Validation
Viral clearance validation is performed in specialized labs, independent from the production site, to ensure that virus inactivation and removal steps are effective and compliant.
In this process, model viruses are spiked into raw materials or intermediates at a reduced scale to simulate actual manufacturing conditions. The remaining virus levels are measured post-treatment to confirm the effectiveness of clearance steps.
Because this validation requires high-purity, high-titer viruses, any compromise in virus quality may affect the reliability of process validation.
Cefety Bioscience supports clients in validating key virus inactivation and removal methods, including:
● Low pH treatment
● Solvent/detergent inactivation
● Chromatography
● Nanofiltration
3. Customized virus test services
Cefety Bioscience operates a dedicated virus testing center covering 2,400 square meters, equipped with specialized BSL-2 certified laboratories for:
● Mycoplasma testing
● Viral assays
● Cell-based testing
● Molecular diagnostics
With deep expertise in method development, validation, and GLP/GMP-compliant testing, our team delivers fully customized virus testing solutions tailored to your project's needs.
Our Services
We provide a full range of biosafety testing and assay development solutions, including:
1.Cell Bank Characterization
2.Virus Bank Characterization
3.Unprocessed Bulk (UPB) Release Testing
4.Viral Clearance Validation
5.Customized Product Testing & Assay Development
We offer a wide range of testing and development services to support biologics and biopharmaceutical manufacturing:
● Cell Bank Testing
● Virus Bank Testing
● Intermediate Product Release Testing
● Viral Clearance Validation
● Customized Testing & Assay Development
Our services support a wide range of biological products, including:
● Biologics
● Cell and gene therapies
● Nucleic acid drugs
● Vaccines
Our facility is equipped with over 110 advanced instruments, including:
● Ultra-high-speed refrigerated centrifuge (Hitachi)
● Automated chromatography system (GE ÄKTA Pure)
● qPCR instruments
● High-pressure steam sterilizer
● CO₂ incubator (Binder)
● Multiple biosafety cabinets and specialized cleanroom equipment
Cefety Bioscience has a strong track record in supporting regulatory submissions and marketed products:
● 45 full-scale cell bank projects completed
● 31 with successful IND approvals
● 48 viral clearance validation projects
● 21 with IND approvals
● 2 post-marketing change projects completed
● 3 BLA projects currently in progress
● 1 approved project with post-market changes
● 2 UPB release projects for marketed products underway
1.Compliant with GMP and GLP standards (China, U.S., EU)
2.Proven experience in global IND/BLA approvals
3.Certified: ISO 9001, CMA, CNAS, BSL-2, FDA FEI
4.Open to official and client audits
5.Passed EU QP and NMPA inspections
6.Authorized for release testing of marketed products
7.Strong track record in BLA-scale viral clearance
|
Company Name: |
Cefety Bioscience (Suzhou) Co., Ltd. |
Type of company: |
Enterprise Units () |
Place of Origin: |
Beijing |
Company Size: |
|
Registered Capital: |
Not filled |
Year of Registration: |
2002 |
Data certification: |
Enterprise data through authenticate
|
Industry: |
|
|